Gilead Sciences today
As of 02.21.2025 21:00
- 52-week range
- $ 62.07
▼
$ 111.03
- Dividend yield
- 2.80%
- P/e ratio.
- 297.16
- Value is valuable
- $ 102.08
Gilead Sciences Inc. Nasdak: Guild The shares grew to a new 52-week maximum in 106.69 US dollars recently in the fourth quarter of 2024. After he slept for so many years, the shares finally discovered a percentage again, reaching prices that were not seen in a decade. The medical sector company was mainly known mainly due to its widely advertised dispute with the participation of Vovaldi in 2013, its treatment in the amount of $ 84,000 for hepatitis C (HEP C).
12-week treatment was the first and only treatment in the world from HEP C, but the cost made it exorbitantly high even for those who had medical insurance. Disputes about $ 1,000 per drug for the tablet ultimately left after the investigation of the financing of the Senate and the new competition from Abbvie Inc. NYSE: ABBV In subsequent years, antivirus (DAAS).
Gilead defended his prices as the highest in the world at that time, arguing that the long -term savings of the cost of treating HEP C have much outweighed the costs of eradicating the disease. These are the 4 reasons why Gilead Sciences shares have much more rise opportunities.
1) Gilead announced reliable income and increased leadership
GILEAD Sciences stocks forecast today
$ 102.08
-7.16% of the lackModerate purchase
Based on 29 analyst ratings
| High forecast | $ 125.00 |
|---|---|
| Average forecast | $ 102.08 |
| Low forecast | $ 69.00 |
GILEAD SCENCES stock forecasts
In his income report for 4 quarters of 2024, Gilead published an inexpensive income of $ 1.90 per share, surpassing the consensus estimates for 16 cents. Revenue increased by 7% year to 7.57 billion dollars. The United States, crushing consensus estimates in the amount of 7.15 billion dollars. USA. The increase was due to higher sales of the product and lower acquired in process research and development. The gross margin of the product increased to 79% in 4 quarter compared to 70% in the previous year. The company brought $ 3 billion in the operational cash flow and closed a year with 10 billion dollars in cash and cash equivalents.
GILEAD released an increase during the entire 2025 in 2025 from 7.70 to $ 8.10, exceeding consensus estimates of $ 7.61. It is expected that sales of products will be from 28.2 to 28.6 billion dollars. The United States, including Veklury sales amounted to $ 1.4 billion, which is its treatment with Covid-19.
2) HIV franchise, oncology and Galead liver disease continues to grow
In 2024, Gilead published an increase of 8% in races up to 19.6 billion dollars. The United States is on the sale of HIV products, which is due to higher demand and a higher average realized price. Biktarvy sales increased by 13% to 13.4 billion dollars, due to higher demand. Descovy sales increased by 6% to 2.1 billion dollars, also due to higher demand. Sales of a portfolio of liver diseases increased by 9% to $ 3 billion. Sales of treating breast cancer in Chelvi grew by 24% to 1.3 billion dollars, which caused an increase in demand in all regions. GILEAD sales for YESCARTA cancer and TECARTUS sales increased by 5% and 9%, respectively.
3) Galead vaccine is 100% effective and will be launched in the summer of 2025.
Gilead has achieved a breakthrough in the treatment of HIV with the help of the drug Lenacapavir, which had 100% for 1 and 99.9% in research 2 targets 2 in HIV prevention. Lenacapavir, an antiviral drug sold under the Sunlenca trademark, was approved for the treatment of HIV-1 with several drugs.
The company submitted a new application for medicines in FDA to treat Lenacapavir for HIV prevention at the end of December 2024. The drug was given the status to refer to the breakthrough treatment of FDA (BTD) to accelerate approval. Gilead expects to start in the United States in the summer of 2025 and in Europe by the end of 2025.
4) Gild Stock forms a gap of a bull -flag
A model of a bull flag consists of two parts. Firstly, the flagpole is a steep upside down in the reserve that ends at its peak. Then the flag forms consolidation with parallel descending fashion lines. The sample is confirmed when the promotion breaks over the upper line of the trend and exceeds the peak of the flagpole.
The guild launched a daily gap of the bull by gap after $ 96.28 after his wage in the 4th quarter. The upper gap fills out support for 100.83 dollars. The guild reached a 52-week maximum of $ 106.69 before retreating. The consensus target price is $ 101.33, and the largest target price of the analyst is $ 125.00.
VWAP daily support is $ 96.07, and the daily RSI begins to slide on 68-point. FIB rollback levels are $ 101.53, $ 96.81, $ 92.87, US dollars and 89.15 US dollars.
Bull investors can consider the possibility of using cash, at the levels of FIB rollback to buy DIP. In the case of the appointment of shares, then writing a coated call at the levels of increase FIB performs a wheel strategy for income in addition to its 2.96% annual dividend profitability.
Before considering the GILEAD sciences, you will want to hear it.
Marketbeat monitors the highest and most effective analysts with the most effective Wall Street analysts and promotions that they recommend to their customers daily. Marketbeat has identified five shares that leading analysts quietly whisper to their clients to buy now before the wider market wins … and Gilead Sciences was not on the list.
While Gilead Sciences currently has a “moderate purchase” rating among analysts, analysts with the highest rating believe that these five promotions are better buying.
View five shares here
Want to know when you can finally invest in SpaceX, Starlink or X.ai? Enter your email address to find out when Elon Musk will finally allow these companies to IPO.
Get this free report